POZEN
POZEN sponsors 24 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 23 completed. 12 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastric Ulcer, with 1 trials.
Trial Pipeline
24 total, page 1 of 1
A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540
NCT01557335
Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers
NCT00995410
A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
NCT00961350
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
NCT00960869
A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels
NCT00749385
Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib
NCT00729495
Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations
NCT00692055
Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib
NCT00700687
Study Evaluating the Effect of Food on the Bioavailability of PN400 Components
NCT00676442
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
NCT00664560
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
NCT00665431
Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations
NCT00665743
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
NCT00527787
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec
NCT00594854
A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)
NCT00527904
A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin
NCT00441519
An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers
NCT00442208
To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin
NCT00442052
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
NCT00367211
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.
NCT00293657
Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy
NCT00293631
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches
NCT00433732
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches
NCT00434083
The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months
NCT00442221
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 2 |
| Phase 3 | 12 |
Therapeutic Areas
What the Pipeline for POZEN Shows
According to the ClinicalTrials.gov registry, POZEN is linked to 24 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 23 are already marked complete, representing roughly 96% of the total.
The phase mix for POZEN reports 12 late-stage studies (Phase 3 and Phase 4 combined) and 12 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for POZEN is Gastric Ulcer with 1 linked trial, and 4 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.